A fractured service: The latest advice on osteoporosis

British Journal of General Practice

Volumn 59, Issue 561, 2009, Pages 239-241

  Cooper, Alun ^a  

^a Bridge Medical Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RALOXIFENE; STRONTIUM RANELATE;

BONE DENSITY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDITORIAL; FRAGILITY FRACTURE; GENERAL PRACTICE; HEALTH SERVICE; HUMAN; INCIDENCE; OSTEOPOROSIS; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RISK ASSESSMENT; RISK FACTOR; AGED; FEMALE; FRACTURE; MALE; MIDDLE AGED;

AGED; FEMALE; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 65349186214     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: 10.3399/bjgp09X420293     Document Type: Editorial

References (17)

1. Van Staa TP, Dennison EM, Leufkaus HG. Epidemiology of fractures in England and Wales. Bone 201; 29(6): 517-522.
2. Cooper C, Atkinson EJ, Jacobsen SJ. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993; 137: 1001-1005.
3. Health and Social Care Information Centre. Hospital Episode Statistics online. Inpatient data. http://www.hesonline.org.uk/Ease/servlet/ ContentServer?siteID=1937&categoryID=192 (accessed 5 Mar 2009).
4. Lindsay R. The burden of osteoporosis: cost. Am J Med 1995; 98(2a): 95-115.
5. Department of Health. The National Service Framework for older people. http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/ DH_4003066IdcService=GET_FILE&dID=15669&Rendition=Web (accessed 5 Mar 2009).
6. Kanis JA, Burlet N, Cooper C. European guidance for the diagnosis and management of osteoporosis in post menopausal women. Osteaporosis Int 2008; 19: 399-428.
7. Verdijk NA, Romeijnders AC, Ruskus JJ, et al. Validation of the Dutch guidelines for dual X-ray absorptiometry measurement. Br J Gen Pract 2009; 59: 256-260.
8. Alphen aan den Rijn. Osteoporose Tweede herziene richtlijn. Van Zuiden Communications BV, 2002.
9. Elders PJM, Leusink G, Graafmans WC, et al. NHG-Standard osteoporose. Huisarts Wet 2005; 48(11): 559-570.
10. Royal College of Physicians. Osteoporosis - clinical guidelines for prevention and treatment: update on pharmacological interventions and an algorithm for management. London: RCP, 2000.
11. Bone and Tooth Society, National Osteoporosis Society, Royal College of Physicans. Glucocorticoid-induced osteoporosis; guidelines for prevention and treatment. London: RCP, 2002.
12. National Institute for Health and Clinical Excellence. Bisphosphonates (alendronate, etidronate, risedronate) selective oestrogen receptor modulators (raloxifene) and parathyroid hormone for the secondary prevention of osteoporotic fragility fractures in post menopausal women. TA 87. London: NICE, 2005.
13. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. TA 161. London: NICE, 2008.
14. National Institute for Health and Clinical Excellence. Osteoporosis - primary prevention. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. TA 160. London: NICE, 2008.
15. National Osteoporosis Guideline Group on behalf of the Bone and Tooth Society, British Geriatric Society, British Orthopaedic Association, British Society Rheumatology, National Osteoporosis Society, Osteoporosis 2000, Osteoporosis Dorset, Primary Care Rheumatology Society, and Society for Endocrinology. Osteoporosis: clinical guidelines for prevention and treatment. London, NOGG: 2008.
16. Kanis J, McClusky E, Johonsson H. National Osteoporosis Guidelines Group. Case study for the management of osteoporosis with FRAX®-assessment and intervention thresholds for the UK. Osteoporosis Int 2008; 19(10): 1395-1408.
17. Kanis J, Adams J, Burgstrom F. The cost-effectiveness of Alendronate in the management of osteoporosis. Bone 2008; 42(1): 4-15.